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ABSTRACT
MicroRNA expression can be exploited to define tumor prognosis and stratification 
for precision medicine. It remains unclear whether prognostic microRNA signatures 
are exclusively tumor grade and/or molecular subtype-specific, or whether common 
signatures of aggressive clinical behavior can be identified. Here, we defined 
microRNAs that are associated with good and poor prognosis in grade III and IV 
gliomas using data from The Cancer Genome Atlas. Pathway analysis of microRNA 
targets that are differentially expressed in good and poor prognosis glioma identified 
a link to oligodendrocyte development. Notably, a microRNA expression profile that 
is characteristic of a specific oligodendrocyte precursor cell type (OP1) correlates 
with microRNA expression from 597 of these tumors and is consistently associated 
with poor patient outcome in grade III and IV gliomas. Our study reveals grade-
independent and subtype-independent prognostic molecular signatures in high-grade 
glioma and provides a framework for investigating the mechanisms of brain tumor 
aggressiveness.
INTRODUCTION
Malignant gliomas comprise the grade III and IV 
gliomas as defined by the World Health Organization [1]. 
Glioblastoma multiforme (GBM, WHO Grade IV) has a 
median survival of 12-15 months and can arise de novo, 
or following progression from grade III disease/anaplastic 
astrocytoma (GIIIA), which has five-year survival rates 
of 24% [2,3]. Genomic biomarkers of malignant glioma 
include isocitrate dehydrogenase 1/2 (IDH1/2) mutations, 
O-6-methylguanine-DNA methyltransferase (MGMT) 
promoter methylation status and 1p19q co-deletion, 
and these markers provide information on prognosis 
and response to treatment [4-6]. It has also been shown 
recently that hypermethylation at a large number of loci, 
known as the glioma CpG island methylator phenotype 
(G-CIMP), confers good prognosis in these tumors [7]. 
Molecular subtypes of GBM have also been defined 
by clustering according to cell type-specific mRNA 
expression patterns [8,9]. Verhaak et al. identified 
classical, proneural, neural, and mesenchymal subtypes 
of GBM using mRNA expression, somatic mutation, and 
copy number data obtained from the cancer genome atlas 
(TCGA, [10]) [8,11]. Interestingly, clustering analysis of 
signature gene expression patterns of the four subtypes 
with expression patterns from murine neural cells showed 
that they are reminiscent of specific neural cell types, 
for example the proneural class has an oligodendrocyte 
rather than astrocyte signature. The proneural GBM 
subtype is also particularly refractory to the current 
standard treatment of radiotherapy and temozolomide and 
a very recent study by Ozawa et al. indicates that most 
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GBM subtypes can arise from a common proneural-like 
precursor cell [12]. A consistent body of literature supports 
the notion that the presence of less differentiated cells in 
cancer confers a poorer prognosis and it may therefore 
be possible to identify common signatures of aggressive 
clinical behavior in glioma based on progenitor cell types 
[12-16].
In this context, microRNAs may be relevant, as 
changes in microRNA expression are emerging as a 
common feature of both neural development and glioma 
biology [17]. MicroRNAs are short non-coding RNAs that 
typically bind to the 3’ untranslated region of mRNAs and 
act to induce mRNA degradation or reduce translation. 
MicroRNAs have roles in the maintenance of brain 
functions throughout life and are extensively dysregulated 
in cancer [18,19]. In brain tumors they have been shown to 
promote ‘stemness’ or inhibit differentiation, consequently 
maintaining tumorigenesis [20]. Their expression is also 
altered in stem-like compartments of both brain tumors and 
other tumors [21-26]. In addition, microRNAs modulate 
neural differentiation and their expression patterns have 
been shown to be distinct at different cellular stages of 
differentiation, including oligodendrocyte precursor (OP) 
differentiation [27]. The presence of stem-like cells in 
brain cancer has been shown to be associated with more 
aggressive, treatment resistant tumors [13,14,16]. It is 
established that microRNAs have a role in maintaining a 
specific differentiation phenotype but it remains unclear 
whether prognostic microRNA signatures are exclusively 
tumor grade and/or molecular subtype-specific, or 
whether common signatures, for example associated 
with differentiation status, can be identified [23]. Here 
we have used a computational approach to test the 
hypothesis that differential microRNA expression profiles 
in groups of glioma patients with good and poor prognosis 
reflect changes in progenitor development pathways. 
We therefore correlated the microRNA expression 
changes between good and poor prognosis groups with 
microRNA expression changes in the OP differentiation 
pathway. Notably, OP differentiation can be modeled in 
vitro using embryonic stem cells (ESCs) that adopt an 
oligodendrocyte cell fate in a step-wise fashion using 
instructive cell culture conditions [27]. The differentiation 
steps include embryoid bodies (EBs), a neural progenitor 
cell state (NP), the oligodendrocyte progenitor stages OP1, 
OP2, and OP3 and the fully differentiated oligodendrocyte 
lineage (OL). Analysis of microRNA profiles of these 
cell types showed that expression changes during OP 
differentiation correlate with prognostic microRNA 
expression changes in malignant glioma. This correlation 
is most apparent for the OP1 cell stage, which consistently 
predicts survival (in >500 gliomas), hence suggesting a 
prognostic signature of aggressive clinical behavior that is 
independent of grade and malignant brain tumor subtype.
RESULTS
Identification of a high-grade glioma microRNA 
signature associated with poor patient survival
To investigate candidate prognostic microRNAs that 
are associated with high-grade brain tumors (GIIIA and 
GBM) through a differential TCGA microRNA expression 
analysis, we developed the computational pipeline shown 
in Figure 1. Based on TCGA patient survival data [28], we 
defined suitable filter criteria indicative of good prognosis 
(>48 months for GIIIA and GBM) and poor prognosis 
(<10 months for GIIIA and <4 months for GBM). These 
cut-offs were decided by assessing the the top and bottom 
10% of survival times in the TCGA cohort and including 
all patients with sufficient clinical and microRNA data. 
This yielded a total of 534 mature microRNAs from 27 
GBM and 16 GIIIA tumors, respectively (Fig. 1, Table 1). 
Based on this dataset, we first determined the microRNAs 
that are differentially expressed between the good and 
poor prognosis groups within GBM and GIIIA specimens, 
separately. To minimize the false discovery rate, we used 
EdgeR and Limma including multiple testing correction 
procedures for microarray and next generation sequencing 
analysis [29-31]. Our approach identified 11 microRNAs 
that are significantly differentially expressed (with log 
fold changes between -1.27 and 6.39) in good versus poor 
prognosis groups in GBM, and 19 in GIIIAs (with log fold 
changes between -1.28 and 2.20). Five of the 11 candidate 
GBM microRNAs were lower in the poor prognosis group 
(Fig. 2a), whereas only 2 of the 19 GIIIA microRNAs 
were lower in the poor prognosis GIIIA group (Fig. 
2b). The most strongly (>5 fold) increased microRNAs 
(miR-10a, miR-196b, miR-211) were all within the poor 
prognosis GIIIA group. This is consistent with previous 
data suggesting that miR-10a and miR-211 are implicated 
in progression and treatment resistance in malignant 
glioma [32,33].
Overall, our intra-grade glioma microRNA 
comparison of good and poor prognosis only yielded 
three microRNAs, the oncomiR miR-21, the apoptosis 
regulator miR-148a, and the tumor suppressor regulator 
miR-222 that could serve as candidate predictors of poor 
prognosis in both GBM and GIIIA [34-36]. This low 
overlap between GBM and GIIIA candidate prognostic 
microRNAs raises the question as to whether it is possible 
to identify a common microRNA signature for high-grade 
glioma, or whether the statistical power of the intra-grade 
comparison approach is insufficient to reveal a GBM/
GIIIA poor prognosis signature. To address this question 
and to increase statistical power in our differential 
microRNA expression analysis, we combined the z-values 
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Table 1: Characteristics of the grade III astrocytoma and glioblastoma TCGA tumors in poor and good 
prognosis groups.
  GIIIA GBM
  
Good progno-
sis (>48 months, 
n=6)
Poor prognosis 
(<18 months, 
n=10)
Good progno-
sis (>48 months, 
n=13)
Poor progno-
sis (<4 months, 
n=14)
Age at Diagnosis  40.5 59.5 41.5 61.9
Overall Survival  87.0% 8.6% 83.4% 2.7
Gender Male 67% 40% 62% 50%
 Female 33% 60% 38% 50%
IDH1 mutation 
status Mutated 100% 10% 0% 0%
 WT 0% 90% 100% 100%
Figure 1: A computational analysis identifies common prognostic molecular signatures in high-grade astrocytoma. (A) 
Differentially expressed microRNAs were identified separately in GIIIA and GBM and data were merged to create a common high-grade 
microRNA profile associated with prognosis. Targets of significant microRNAs were predicted and pathway analysis suggests that gene 
expression pathways associated with OP cells may predict patient outcome. Fold change data for each microRNA differentially expressed 
between each cell in the OP differentiation pathway was correlated with microRNA fold change data calculated between poor and good 
prognosis groups (and IDH1 mutation/IDHwt tumors) in GIIIA and GBM. (B) MicroRNA expression profiles for all 597 TCGA malignant 
glioma (GIIIA and GBM) were correlated with the expression values of each cell type in the OP differentiation pathway [27].
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(Z
r,combined
) from the good and poor prognosis groups of 
GIIIA (Z
r,III
) and GBM (Z
r,IV
) accounting for differences in 
microRNA expression profiling platforms using a suitable 
computational algorithm based on the formula for each 
microRNA, r, including fold change, FC, and standard 
error (SE):
 Z
r,III 
= log(FC
r,III
)/SE
r,III
 Z
r,IV 
= log(FC
r,IV
)/SE
r,IV
 
 Z
r,combined
 = (Z
r,III
 + Z
r,III
)/ √2
Under the null hypothesis that Z
r,III
 and Z
r,IV
 are both 
N(0,1) and independent, Z
r,combined
 will also be N(0,1) and 
can therefore be interpreted as a Z value.
This approach yielded a pool of 216 microRNAs 
whose differential expression was analyzed across all 
relevant poor/good prognosis GBM and GIIIA TCGA 
specimens, thereby creating z-scores and p-values for 
the individual microRNAs. Using the multiple testing 
corrected p-values for each microRNA yielded 63 
microRNAs that significantly change expression between 
good and poor prognosis high-grade gliomas as indicated 
by a >2 fold change of standard deviations from the mean 
microRNA fold change (FDR<0.05) (Fig. 2c). 
Our results are consistent with a hypothesis that a 
pool of 63 microRNAs form part of a molecular network 
that is associated with and/or drives aggressive clinical 
behavior in high-grade gliomas. To identify the molecular 
pathways that are likely regulated by the 63 candidate 
prognostic microRNAs, we predicted their mRNA targets 
using standard bioinformatic approaches. In order to focus 
on the mRNA targets that are involved in prognosis, we 
first enriched for those that are associated with either good 
or poor prognosis. We compared good prognosis and poor 
prognosis mRNAs in GIIIA and GBM (Table 1) using 
the same criteria as those described above for microRNA 
analysis. The mRNA data (z-scores and p-values) for 
GIIIA and GBM were merged resulting in 4259 mRNAs 
with significant (p<0.05) >2 fold changes. The targets 
of the 63 microRNAs associated with patient outcome 
were predicted from the 4259 mRNAs using the target 
prediction databases Miranda, Pictar and Targetscan [37-
39]. We only used targets that were present in at least two 
of these databases, resulting in 1618 predicted targets for 
the microRNAs (Supplementary list S1). Subsequently, 
Figure 2: (A-B) Fold changes of the differentially expressed microRNA expression between the good and poor prognosis 
groups in GIIIA and GBM. (C) Plot of the microRNAs differentially expressed between good and poor prognosis groups when data 
from GBM and GIIIA are combined. 63 microRNAs (in red) are significantly altered between good and poor prognosis groups (p<0.05) and 
have a z-value of at least 2/-2. (D) The targets of the 63 microRNAs associated with patient outcome were predicted and pathway analysis 
revealed a significant enrichment of genes involved in several OP-related pathways. 
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we entered these mRNAs into the Metacore software 
and carried out a pathway analysis revealing significant 
enrichment of genes involved in several cancer-related 
pathways (Fig. 2d). These pathways included IGF and 
AKT signalling, epigenetic and transcriptional regulation, 
growth factor, androgen and chemokine- effectors, and 
cytoskeletal remodeling. Interestingly, four of these 
pathways are linked with OP cell fate decisions such as 
survival, proliferation, differentiation, and myelination. 
This provides correlative evidence to suggest that the 
microRNAs associated with survival in high-grade glioma 
have roles in OP differentiation pathways.
OP gene expression signatures correlate with poor 
prognosis in glioma 
To further determine whether the activity 
of microRNAs in different cell stages of the OP 
differentiation pathway are associated with malignant 
glioma patient outcome, we accessed published data 
describing microRNA profiles associated with stages in 
the differentiation of ESCs into oligodendrocytes [27]. Our 
initial hypothesis was that presence of less differentiated 
oligodendrocyte cells in glioma confers a poorer 
prognosis. To this end, we questioned whether microRNA 
expression changes throughout OP differentiation 
resemble the prognostic microRNA expression pattern 
of malignant glioma. First, we calculated fold changes 
between each progenitor cell type in the OP differentiation 
pathway and correlated these with the fold differences 
between poor prognosis and good prognosis samples of 
GIIIA or GBM (Fig. 2a-b). Only microRNAs that are 
significantly differentially expressed between each stage 
of the OP differentiation pathway and with at least a 
2-fold change in expression were used. The OP2 to OP3 
stage was omitted, as there were too few differentially 
expressed microRNAs between these cell types. In GIIIA, 
the microRNA expression differences between good and 
poor prognostic cases correlated directly with the changes 
associated with differentiation from NP to GP (correlation 
coefficient = 0.50, p<0.05), which was not evident in 
GBMs. In both grades, the expression differences between 
good and poor prognosis showed a negative correlation 
with the changes associated with differentiation from OP1 
to OP2 (correlation coefficient -0.54 for GIIIA and -0.47 
for GBM, p<0.05) (Fig. 3). Next, we tested whether these 
correlations are a result of non-specific correlations with 
any ESC differentiation pathway (including non-neural 
lineages), or whether these high correlations are specific 
for neural differentiation. We used expression data from 
a study comparing microRNA expression between ESC 
cells and hematopoietic progenitors (HPs) and between 
neural stem cells (NSCs) and neural progenitors (NPs) 
[40-41]. We correlated the differences in the differentially 
expressed microRNAs between ESCs and HPs and NSC 
and NP cells with the differential microRNA expression 
patterns between good and poor prognosis in GIIIA and 
GBM. This approach revealed no significant correlations 
(p>0.05, ρ correlation coefficient <0.15) indicating that the 
microRNA expression differences between good and poor 
prognosis of malignant glioma are specifically correlated 
Figure 3: Correlation coefficients comparing the fold change of microRNA expression between each stage in the OP 
pathway and the GIIIA and GBM good and poor prognosis groups. The top 6 rows relate to data from Letzen et al. and the 
bottom rows refer to data from Goff et al. and Risueño et al. [27,40,41]. The highest negative correlation is the transition from OP1 to OP2 
and the highest positive correlation is the transition from GP to OP1.
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with microRNA expression changes in OP differentiation, 
and not with other differentiation pathways (Fig. 3).
A notable difference in good and poor prognosis 
GIIIA patients studied here was their IDH mutation status 
(Table 1), which is used to classify patients clinically; 
those with the mutation are usually proneural tumors 
and have a favorable prognosis [5,6]. In our cohort, all 
the good prognosis patients had an IDH mutation, while 
only one poor prognosis patient was IDH mutated. It could 
be argued that the difference in microRNA expression 
between these two groups is simply due to different 
biology associated with the presence or absence of an IDH 
mutation. To test this possibility, we obtained sequencing 
data for IDH mutated (IDHmut, n=139) and IDH wild-type 
(IDHwt, n=39) gliomas (combining data for both grade 
II and III glioma for added statistical power) from the 
TCGA and determined microRNA expression differences 
between the two groups using the criteria previously 
stated. The microRNA expression fold differences 
between IDHwt and IDHmut were correlated with the 
fold changes between each stage in the OP differentiation 
pathway. The only significant correlation observed was an 
inverse correlation between IDHmut and IDHwt and OP1 
to OP2. Good versus poor prognosis GIIIA and GBM also 
correlated with this OP differentiation stage. Critically, 
the fold differences between IDHmut and IDHwt did not 
correlate with the changes during differentiation from NP 
to GP (p<0.05, ρ correlation coefficient < -0.34). Therefore 
we conclude that the correlation we have shown between 
prognosis and OP stage differentiation is independent of 
IDH mutation status.
Correlation of microRNA expression with the OP 
cell stage is associated with glioma survival
Correlations of the microRNA expression 
differences between good and poor prognosis cases and 
between neural differentiation stages imply that correlation 
with the OP1 cell type is most closely related to prognosis. 
Figure 4: (A) Density plots of the Spearman’s correlation coefficients for each cell type with all GIIIA and GBM tumors 
in the TCGA. All cell types in the OP differentiation pathway show positive correlation of microRNA expression with each tumor. The 
oligodendrocyte lineage and OP1 cells show the most significant positive correlations with the tumors. (B) Heatmap of correlation of each 
GIIIA/GBM tumor with each OP cell type. (C) Hazard ratios from Cox regression analysis of the correlation patterns of each cell type 
shows that OP1 microRNA expression correlation is the most predictive in terms of prognosis. MicroRNA profiles of all cell types were 
significantly associated with survival (p<0.05); however, there is a peak in statistical power when OP1 cells are used as the predictor. (D) 
Kaplan Meier plot of the OP1 correlation coefficients for grade III and IV gliomas. Groups are separated above and below the median 
correlation of microRNA expression between OP1 and tumor.
Oncoscience258www.impactjournals.com/oncoscience
In order to examine this hypothesis, we correlated 
the microRNA expression profiles of each differentiation 
stage in the oligodendrocyte differentiation pathway with 
microRNA expression profiles of 39 GIIIA, 558 GBM and 
10 non-tumor samples from the TCGA. Only microRNAs 
present in all platforms (sequencing and microarray) were 
used (150 microRNAs) (Supplementary list S2). The 
majority of the 597 tumors positively correlated with each 
cell type in the OP differentiation pathway. Seven GIIIA 
tumors did not correlate with OP2 or OP3 microRNA 
expression, and two GIIIA tumors did not correlate with 
OP2 expression. Across all tumors assessed, the highest 
correlations were with OP1 and oligodendrocyte lineage 
(OL) cell types microRNA expression patterns (Fig. 4a 
and b). The cell type that correlated most positively with 
tumors was OP1. This cell type was most correlated with 
each tumor type and also ten non-tumor samples. 
Twenty-three GBMs had the highest correlation 
with OL and one GBM had the highest correlation with 
glial restricted precursor (GP). Average correlation with 
OP1 was 0.60 for GIIIA, 0.93 for GBM, 0.69 for the 
mesenchymal subtype of GBM (n=155), 0.67 for the 
classical the GBM subtype (n=143), 0.36 for G-CIMP 
GBM subtype (n=38), 0.54 for neural GBM (n=82), 0.58 
for proneural GBM (n= 97) [1,6,11], and 0.88 for non-
tumor samples [11]. These results indicate that GBM is 
most positively correlated with OP expression patterns. 
To determine the association of the OP 
differentiation cell stages with high-grade glioma patient 
survival, the correlation values for each of the eight cell 
types in the OP differentiation pathway with all 597 
tumors in the TCGA were assessed for association with 
survival using Cox regression analysis. Rho (ρ) values 
(Spearman’s coefficient) for all cell types were significant 
negative predictors (p<0.05) of survival. The highest 
hazard ratio was for correlations with the OP1 cell type 
(Fig. 4c), which indicates that gliomas with microRNA 
expression patterns similar to OP1 cells have a poorer 
patient outcome (Cox regression HR = 13.02, 95% CI = 
3.77-45.04, p = 5.02e-05) (Fig. 4d). Taken together, our 
results suggest that the most aggressive malignant gliomas 
(both GIIIA and GBM) have a microRNA expression 
pattern that aligns with expression patterns characteristic 
of the OP1 cell stage.
DISCUSSION
Prognostic glioma microRNAs align with OP 
pathways
There has been considerable discussion over 
subtyping of GBM based on expression and copy number 
data. However, so far this approach has not delivered 
robust clinical biomarkers and the field is further 
complicated by data confirming that subtypes can co-
exist within the same tumor thereby creating a diversity 
of oncogenic transcriptional programs that contribute to 
treatment resistance [42,43].
Models of glioma suggest these tumors may be 
defined by the initiating cell type or the type of initiating 
mutation [44]. Despite these observations, the glial cell 
of origin in different histological types of glioma remains 
unclear [45]. It has been proposed that OPs may fill 
this role in some subtypes and this is supported by data 
suggesting that mesenchymal GBM can arise from a 
proneural-like precursor [12, 46].
Using integrated mRNA and microRNA expression 
data we have identified that prognostic microRNA 
expression patterns in malignant glioma correlate with 
microRNA expression changes during oligodendrocyte 
differentiation (Fig. 2d). Our study is novel in identifying 
grade-independent and subtype-independent prognosis 
prediction using microRNAs as biomarkers, which are 
stable in clinical samples, with additional validation, 
and may be appropriate for implementation into clinical 
practice [47].
MicroRNA expression changes associated with 
cellular transitions between OP1 and OP2 (GIIIA and 
GBM, Fig. 3) suggest that more aggressive tumors have 
more cells with OP1-like expression patterns, or are simply 
less differentiated.. Whether these are non-malignant OP1s 
present within the tumor , or simply less differentiated 
cells, mass, malignant cells with similarities to these cells 
cannot be ascertained from our data. The tumor samples 
under study here were defined by the TCGA as having at 
least 70% tumor nuclei which suggests this is unlikely to 
be a non-malignant population of cells.
In line with of our computational results, OPs have 
been shown to stimulate a more aggressive phenotype 
by promoting neo-vascularization of glioma and are 
present at the invasive front of high grade tumors [48]. 
Initial neoplasia-generating aberrations in NSCs can only 
become transforming upon differentiation into an OP, 
suggesting that these cell types are important in tumor 
initiation, as well as defining its behavior [45]. Supporting 
this notion, both proneural and mesenchymal tumors have 
been shown to arise from a common precursor [12,45]. OP 
cells are also implicated in maintaining self-renewal by 
means of asymmetric cell division, supporting both self-
renewal and proliferation in the tumor [49]. These cells 
are also defined by their PDGFRA expression, and recent 
studies show that amplification of this is an initiating event 
in gliomagenesis [12,50,51].
Translational relevance of the OP1 prognostic 
signature
Our results suggest a more OP1-like phenotype 
is associated with a more aggressive tumor (Fig. 4c-d), 
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and presence of these OP1 microRNA patterns predicts 
poorer prognosis. MicroRNA signatures predicting more 
aggressive tumors have been developed in the past, yet 
their relevance to tumor biology is not well understood 
[52-54]. Also, subtype-specific signatures are not easy to 
implement into the clinical routine of standard healthcare 
laboratories due to logistic challenges (i.e. multiple 
testing procedures) and the need for diverse state-of-the-
art profiling platforms (i.e. next generation sequencing) 
as well as high-level bioinformatics/computational 
support. Hence, it would be desirable to replace complex 
prognostic signatures with a few key biomarkers wherever 
possible. For example, Letzen et al describe peaks of miR-
10a and miR-21 expression in OP cells [27] that were both 
significantly increased in our merged data compared to 
other neural cell types and it may therefore be possible 
that these microRNAs alone have the potential to be 
exploited as biomarkers for the presence of OP-like cells. 
Prospective observational clinical trials will be needed to 
address this hypothesis.
Taken together, we provide preliminary data that 
classification of malignant glioma based on microRNA 
expression patterns seen in OPs may predict the outcome 
of the disease, which could not only inform patient 
management but also guide development of novel 
treatments. The statistical power of future work is likely 
to be increased due to the availability of more samples in 
TCGA and other repositories. This is also a principle that 
could be extended to other tumor types, to elucidate the 
characteristic microRNA profiles exhibited in particular by 
poor prognosis tumors.
MATERIALS AND METHODS
MicroRNA and mRNA expression analysis
All computational work was performed in R 
(v2.15.1). Level 3 Agilent microRNA 8×15k microarray, 
G4520A microarray gene expression data and clinical 
information for GBM and non-tumor samples were 
downloaded from The Cancer Genome Atlas (TCGA) 
[28]. Level 3 Illumina HiSeq sequencing data for mature 
microRNA and mRNA expression plus clinical information 
for lower grade gliomas were also downloaded from 
TCGA. Due to the differences in normalization methods 
and quantification artifacts of microarray and sequencing 
platforms, the expression changes within the grades 
were ascertained using appropriate statistical packages 
developed for microarrays and sequencing [29,30]. Then 
these data were merged, rather than direct merging of the 
data prior to differential expression analysis. The good 
and poor prognosis groups of these glioma datasets were 
selected according to the published survival data in the 
TCGA database (Table 1). EdgeR was used to compare 
microRNA and mRNA expression between the two GIIIA 
survival groups and 139 IDH mutated and 39 IDH wild-
type grade II and III tumors [29]. The linear Models for 
Microarray Data (LIMMA) package was used to compare 
microRNA expression for the poor and good prognosis 
groups in GBM [30].
For each microRNA or mRNA, r, the z-scores 
associated with GIIIA (III) and GBM (IV) prognosis were 
calculated separately from their log(fold change, FC) and 
corresponding standard error, SE:
Z
r,III 
= log(FC
r,III
)/SE
r,III
 ; Z
r,IV 
= log(FC
r,IV
)/SE
r,IV
 
Under the joint null hypothesis, log(FC
r,III
) = 
log(FC
r,IV
) = 0, the two z-scores are N(0,1) distributed and 
independent, so the sum Z
r,III 
+ Z
r,II
 is N(0,2). The p-values 
corresponding to the joint null hypothesis were adjusted 
for multiple testing using the Benjamini-Hochberg method 
[31].
Pathway prediction
Miranda, Pictar and Targetscan were used to predict 
targets for differentially expressed microRNAs from the 
differentially expressed mRNAs using the RmiR package 
[37-39, 55]. Targets were only considered if they were 
present in at least two of these databases. The resulting 
targets were entered into the pathway analysis program 
Metacore® (Thomson Reuters).
Analysis of the differentiation pathway
We used data published in Letzen et al, which 
describes the microRNA expression fold changes between 
each cell differentiation stage within the OP differentiation 
pathway including embryonic stem cells (ESCs), neural 
embryoid bodies (EB), neural progenitors (NP), glial 
restricted precursors (GP), oligodendrocyte precursors 
(OP) I, OP II, OP III and the oligodendrocyte lineage (OL) 
[27]. Spearman’s correlation was performed on the fold 
change between good and poor prognosis groups within 
GIIIA and GBM, with the expression changes of the 
significantly differentially expressed microRNAs with at 
least 2-fold change at each stage in the OP differentiation 
pathway. The fold changes of all microRNAs of 
significance between OP cell types were used, regardless 
of their significance for survival. As a control, expression 
values from Taqman PCR microRNA expression between 
ESCs and hematological precursors (HP) as described in 
Risueño et al. and between neural stem cells (NSCs) and 
NPs as described in Goff et al. were used to calculate the Δ 
Ct and perform Spearman’s correlation with the prognosis-
associated fold differences in GIIIA and GBM [40-41]. 
Only microRNAs significantly differentially expressed 
between the ESCs and HPs were used (139 microRNAs) 
in the correlation analysis.
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Correlation of microRNA expression of the OP 
pathway with malignant glioma tumors
Microarray expression data was processed as 
described in Letzen et al. [27] using Agilent Feature 
Extraction software and the gTotalGeneSignal was 
correlated with the level 3 expression data from the TCGA 
GIIIA astrocytoma (n =39), GBM tumors (n=558) and 
non-tumor samples (n=10). Only microRNAs detected 
on all platforms (Agilent microarray G4470C and 
custom TCGA Agilent microarray, and Illumina HiSeq 
sequencing) were included resulting in 150 microRNAs. 
GBMs were classified according to Brennan et al [11]. 
The correlation patterns of each cell type for every tumor 
was analyzed for association with survival using Cox 
regression and log-rank tests.
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